Fig. 4

Analysis of the CRG and CRDEG clusters. (A) Cuproptosis score among three CRGs clusters and CREDGs clusters; (B) Survival probability of high/low group in cuproptosis score model NSCLC patients; (C) Correlation of survival period, survival status, and NSCLC major mutant gene EGFR with two groups in cuproptosis score model; (D) Survival curve of NSCLC patients from different stages; (E) TMB among the two groups of cuproptosis score models and the three gene clusters; (F) TMB in the cuproptosis score model high/low groups; (G, H) Survival probability in the high-/low-TMB group and the high/low-TMB group plus the high/low cuproptosis score; (I) Sankey diagram of the CRGs and CRDEGs subtype clusters, the cuproptosis score group, and the survival status. (*P < 0.05; ** P < 0.01; and *** P < 0.001; Ns, not significant). TMB, tumor mutation burden. EGFR, epidermal growth factor receptor; NSCLC, non-small-cell lung cancer